Combination therapy with oral treprostinil for pulmonary arterial hypertension: a double-blind placebo-controlled clinical trial
Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hypertension (PAH), but the effect on clinical outcomes was unknown.Objectives: To evaluate the effect of oral treprostinil compared with placebo on time to first adjudicated clinical worsening event in parti...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
[March 15, 2020]
|
| In: |
American journal of respiratory and critical care medicine
Year: 2020, Jahrgang: 201, Heft: 6, Pages: 707-717 |
| ISSN: | 1535-4970 |
| DOI: | 10.1164/rccm.201908-1640OC |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1164/rccm.201908-1640OC Verlag, lizenzpflichtig, Volltext: https://www.atsjournals.org/doi/10.1164/rccm.201908-1640OC 
|
| Verfasserangaben: | R. James White, Carlos Jerjes-Sanchez, Gisela Martina Bohns Meyer, Tomas Pulido, Pablo Sepulveda, Kuo Yang Wang, Ekkehard Grünig, Shirish Hiremath, Zaixin Yu, Zhang Gangcheng, Wei Luen James Yip, Shuyang Zhang, Akram Khan, C.Q. Deng, Rob Grover, and Victor F. Tapson; for the FREEDOM-EV investigators |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1694671569 | ||
| 003 | DE-627 | ||
| 005 | 20230427070517.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200416s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1164/rccm.201908-1640OC |2 doi | |
| 035 | |a (DE-627)1694671569 | ||
| 035 | |a (DE-599)KXP1694671569 | ||
| 035 | |a (OCoLC)1341315290 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a White, R. James |e VerfasserIn |0 (DE-588)1196547114 |0 (DE-627)1678181374 |4 aut | |
| 245 | 1 | 0 | |a Combination therapy with oral treprostinil for pulmonary arterial hypertension |b a double-blind placebo-controlled clinical trial |c R. James White, Carlos Jerjes-Sanchez, Gisela Martina Bohns Meyer, Tomas Pulido, Pablo Sepulveda, Kuo Yang Wang, Ekkehard Grünig, Shirish Hiremath, Zaixin Yu, Zhang Gangcheng, Wei Luen James Yip, Shuyang Zhang, Akram Khan, C.Q. Deng, Rob Grover, and Victor F. Tapson; for the FREEDOM-EV investigators |
| 264 | 1 | |c [March 15, 2020] | |
| 300 | |b Diagramme | ||
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 16.04.2020 | ||
| 520 | |a Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hypertension (PAH), but the effect on clinical outcomes was unknown.Objectives: To evaluate the effect of oral treprostinil compared with placebo on time to first adjudicated clinical worsening event in participants with PAH who recently began approved oral monotherapy.Methods: In this event-driven, double-blind study, we randomly allocated 690 participants (1:1 ratio) with PAH to receive placebo or oral treprostinil extended-release tablets three times daily. Eligible participants were using approved oral monotherapy for over 30 days before randomization and had a 6-minute-walk distance 150 m or greater. The primary endpoint was the time to first adjudicated clinical worsening event: death; hospitalization due to worsening PAH; initiation of inhaled or parenteral prostacyclin therapy; disease progression; or unsatisfactory long-term clinical response.Measurements and Main Results: Clinical worsening occurred in 26% of the oral treprostinil group compared with 36% of placebo participants (hazard ratio, 0.74; 95% confidence interval, 0.56-0.97; P = 0.028). Key measures of disease status, including functional class, Borg dyspnea score, and N-terminal pro-brain natriuretic peptide, all favored oral treprostinil treatment at Week 24 and beyond. A noninvasive risk stratification analysis demonstrated that oral treprostinil-assigned participants had a substantially higher mortality risk at baseline but achieved a lower risk profile from Study Weeks 12-60. The most common adverse events in the oral treprostinil group were headache, diarrhea, flushing, nausea, and vomiting.Conclusions: In participants with PAH, addition of oral treprostinil to approved oral monotherapy reduced the risk of clinical worsening.Clinical trial registered with www.clinicaltrials.gov (NCT01560624). | ||
| 700 | 1 | |a Grünig, Ekkehard |e VerfasserIn |0 (DE-588)112535801 |0 (DE-627)618892605 |0 (DE-576)31856694X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of respiratory and critical care medicine |d New York, NY : American Thoracic Society, 1959 |g 201(2020), 6, Seite 707-717 |h Online-Ressource |w (DE-627)26688492X |w (DE-600)1468352-0 |w (DE-576)075961563 |x 1535-4970 |7 nnas |a Combination therapy with oral treprostinil for pulmonary arterial hypertension a double-blind placebo-controlled clinical trial |
| 773 | 1 | 8 | |g volume:201 |g year:2020 |g number:6 |g pages:707-717 |g extent:11 |a Combination therapy with oral treprostinil for pulmonary arterial hypertension a double-blind placebo-controlled clinical trial |
| 856 | 4 | 0 | |u https://doi.org/10.1164/rccm.201908-1640OC |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.atsjournals.org/doi/10.1164/rccm.201908-1640OC |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200416 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 112535801 |a Grünig, Ekkehard |m 112535801:Grünig, Ekkehard |d 910000 |d 950000 |d 950900 |e 910000PG112535801 |e 950000PG112535801 |e 950900PG112535801 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 7 | ||
| 999 | |a KXP-PPN1694671569 |e 3624050567 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title_sort":"Combination therapy with oral treprostinil for pulmonary arterial hypertension","subtitle":"a double-blind placebo-controlled clinical trial","title":"Combination therapy with oral treprostinil for pulmonary arterial hypertension"}],"person":[{"given":"R. James","display":"White, R. James","family":"White","role":"aut"},{"role":"aut","family":"Grünig","display":"Grünig, Ekkehard","given":"Ekkehard"}],"physDesc":[{"noteIll":"Diagramme","extent":"11 S."}],"relHost":[{"id":{"zdb":["1468352-0"],"issn":["1535-4970"],"eki":["26688492X"]},"language":["eng"],"corporate":[{"display":"American Thoracic Society","role":"isb"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"publisher":"American Thoracic Society ; American Lung Association","dateIssuedKey":"1959","publisherPlace":"New York, NY ; New York, NY","dateIssuedDisp":"1959-"}],"titleAlt":[{"title":"AJRCCM online"},{"title":"AJRCCM"},{"title":"American review of respiratory diseases"}],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"American journal of respiratory and critical care medicine","subtitle":"AJRCCM ; an official journal of the American Thoracic Society, Medical Section of the Lung Association","title":"American journal of respiratory and critical care medicine"}],"part":{"extent":"11","year":"2020","issue":"6","volume":"201","text":"201(2020), 6, Seite 707-717","pages":"707-717"},"disp":"Combination therapy with oral treprostinil for pulmonary arterial hypertension a double-blind placebo-controlled clinical trialAmerican journal of respiratory and critical care medicine","recId":"26688492X","pubHistory":["80.1959 -"],"note":["Gesehen am 17.01.2022"]}],"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"[March 15, 2020]"}],"id":{"eki":["1694671569"],"doi":["10.1164/rccm.201908-1640OC"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"name":{"displayForm":["R. James White, Carlos Jerjes-Sanchez, Gisela Martina Bohns Meyer, Tomas Pulido, Pablo Sepulveda, Kuo Yang Wang, Ekkehard Grünig, Shirish Hiremath, Zaixin Yu, Zhang Gangcheng, Wei Luen James Yip, Shuyang Zhang, Akram Khan, C.Q. Deng, Rob Grover, and Victor F. Tapson; for the FREEDOM-EV investigators"]},"recId":"1694671569","note":["Gesehen am 16.04.2020"]} | ||
| SRT | |a WHITERJAMECOMBINATIO1520 | ||